Literature DB >> 17051360

Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis.

Yasunori Kageyama1, Eiji Torikai, Akira Nagano.   

Abstract

The aim of this study was to analyze the change of serum chemokins levels of CXCL16, CX3CL1/Fractalkine, and CXCL10/interferon-gamma inducible protein-10 (IP-10) with rheumatoid arthritis (RA), by infliximab treatment. The effects of infliximab treatment were studied in 23 patients with RA, over a period of 30 weeks. The serum levels of CXCL16, Fractalkine, and IP-10, were measured at the baseline, just before initial treatment, and at 14 and 30 weeks after the initial treatment, with infliximab by ELISA. The higher levels of serum CXCL16 in the RA patients before treatment with infliximab significantly decreased at 14 and 30 weeks after the initial treatment with infliximab, but the serum Fractalkine and IP-10 levels did not decrease significantly. Infliximab treatment significantly lowered the serum levels of CXCL16 in patients with RA. CXCL16 is one of the crucial chemokines regulated by infliximab treatment.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17051360     DOI： 10.1007/s00296-006-0241-1

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  36 in total

1.  Expression of the novel scavenger receptor SR-PSOX in cultured aortic smooth muscle cells and umbilical endothelial cells.

Authors:  Oliver Hofnagel; Birgit Luechtenborg; Gabriele Plenz; Horst Robenek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-04-01       Impact factor: 8.311

2.  Synovial tissue macrophage as a source of the chemotactic cytokine IL-8.

Authors:  A E Koch; S L Kunkel; J C Burrows; H L Evanoff; G K Haines; R M Pope; R M Strieter
Journal:  J Immunol       Date:  1991-10-01       Impact factor: 5.422

Review 3.  Anti-cytokine therapy for rheumatoid arthritis.

Authors:  R N Maini; P C Taylor
Journal:  Annu Rev Med       Date:  2000       Impact factor: 13.739

4.  Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation.

Authors:  Y Pan; C Lloyd; H Zhou; S Dolich; J Deeds; J A Gonzalo; J Vath; M Gosselin; J Ma; B Dussault; E Woolf; G Alperin; J Culpepper; J C Gutierrez-Ramos; D Gearing
Journal:  Nature       Date:  1997-06-05       Impact factor: 49.962

5.  Expression cloning of the STRL33/BONZO/TYMSTRligand reveals elements of CC, CXC, and CX3C chemokines.

Authors:  A Wilbanks; S C Zondlo; K Murphy; S Mak; D Soler; P Langdon; D P Andrew; L Wu; M Briskin
Journal:  J Immunol       Date:  2001-04-15       Impact factor: 5.422

6.  Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells.

Authors:  E Robinson; E C Keystone; T J Schall; N Gillett; E N Fish
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

7.  A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16.

Authors:  Peter J Gough; Kyle J Garton; Paul T Wille; Marcin Rychlewski; Peter J Dempsey; Elaine W Raines
Journal:  J Immunol       Date:  2004-03-15       Impact factor: 5.422

8.  Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.

Authors:  Piotr Adrian Klimiuk; Stanislaw Sierakowski; Izabela Domyslawska; Justyna Chwiecko
Journal:  J Rheumatol       Date:  2004-02       Impact factor: 4.666

9.  The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10.

Authors:  Soeren Abel; Christian Hundhausen; Rolf Mentlein; Alexander Schulte; Theo A Berkhout; Neil Broadway; Dieter Hartmann; Radek Sedlacek; Sebastian Dietrich; Barbara Muetze; Bjoern Schuster; Karl-Josef Kallen; Paul Saftig; Stefan Rose-John; Andreas Ludwig
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

10.  Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.

Authors:  E M Paleolog; S Young; A C Stark; R V McCloskey; M Feldmann; R N Maini
Journal:  Arthritis Rheum       Date:  1998-07
View more
  9 in total

1.  CXCL16 upregulates RANKL expression in rheumatoid arthritis synovial fibroblasts through the JAK2/STAT3 and p38/MAPK signaling pathway.

Authors:  Chang-hong Li; Lin-lin Xu; Jin-xia Zhao; Lin Sun; Zhong-qiang Yao; Xiao-li Deng; Rui Liu; Lin Yang; Rui Xing; Xiang-yuan Liu
Journal:  Inflamm Res       Date:  2015-11-30       Impact factor: 4.575

2.  Overexpression of CXCL16 in lesional psoriatic skin.

Authors:  Shin-Taek Oh; Anja Schramme; Wolfgang Tilgen; Paul Gutwein; Jörg Reichrath
Journal:  Dermatoendocrinol       Date:  2009-03

3.  Serum macrophage migration inhibitory factor levels are correlated with response to tocilizumab therapy in patients with rheumatoid arthritis.

Authors:  Tsuyoshi Kasama; Sakiko Isojima; Masayu Umemura; Hiroyuki Tsukamoto; Takehiro Tokunaga; Hidekazu Furuya; Ryo Yanai; Ryo Takahashi; Masanori Nakamura; Katsunori Inagaki
Journal:  Rheumatol Int       Date:  2013-05-14       Impact factor: 2.631

4.  Immunosuppressive effects of mesenchymal stem cells in collagen-induced mouse arthritis.

Authors:  Fei Mao; Wen-Rong Xu; Hui Qian; Wei Zhu; Yong-Min Yan; Qi-Xiang Shao; Hua-Xi Xu
Journal:  Inflamm Res       Date:  2009-09-10       Impact factor: 4.575

5.  Etanercept treatment reduces the serum levels of interleukin-15 and interferon-gamma inducible protein-10 in patients with rheumatoid arthritis.

Authors:  Tetsuya Ichikawa; Yasunori Kageyama; Hayato Kobayashi; Norihiko Kato; Kunio Tsujimura; Yukio Koide
Journal:  Rheumatol Int       Date:  2010-01-10       Impact factor: 2.631

6.  Differentially Expressed Genes of Natural Killer Cells Can Distinguish Rheumatoid Arthritis Patients from Healthy Controls.

Authors:  Noha Mousaad Elemam; Mahmood Yaseen Hachim; Suad Hannawi; Azzam A Maghazachi
Journal:  Genes (Basel)       Date:  2020-04-30       Impact factor: 4.096

Review 7.  The Interplay Between Monocytes/Macrophages and CD4(+) T Cell Subsets in Rheumatoid Arthritis.

Authors:  Ceri A Roberts; Abigail K Dickinson; Leonie S Taams
Journal:  Front Immunol       Date:  2015-11-19       Impact factor: 7.561

8.  Heightened Levels of Antimicrobial Response Factors in Patients With Rheumatoid Arthritis.

Authors:  Prathapan Ayyappan; Robert Z Harms; Jennifer A Seifert; Elizabeth A Bemis; Marie L Feser; Kevin D Deane; M Kristen Demoruelle; Ted R Mikuls; V Michael Holers; Nora E Sarvetnick
Journal:  Front Immunol       Date:  2020-03-20       Impact factor: 7.561

Review 9.  Chemokines and chemokine receptors in arthritis.

Authors:  Zoltan Szekanecz; Aniko Vegvari; Zoltan Szabo; Alisa E Koch
Journal:  Front Biosci (Schol Ed)       Date:  2010-01-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.